Naturally occurring axonal pruning and neuronal cell death help to sculpt neuronal connections during development, but their mechanistic basis remains poorly understood. Here we report that b-amyloid precursor protein (APP) and death receptor 6 (DR6, also known as TNFRSF21) activate a widespread caspase-dependent self-destruction program. DR6 is broadly expressed by developing neurons, and is required for normal cell body death and axonal pruning both in vivo and after trophic-factor deprivation in vitro. Unlike neuronal cell body apoptosis, which requires caspase 3, we show that axonal degeneration requires caspase 6, which is activated in a punctate pattern that parallels the pattern of axonal fragmentation. DR6 is activated locally by an inactive surface ligand(s) that is released in an active form after trophic-factor deprivation, and we identify APP as a DR6 ligand. Trophic-factor deprivation triggers the shedding of surface APP in a b-secretase (BACE)-dependent manner. Loss-and gain-of-function studies support a model in which a cleaved amino-terminal fragment of APP (N-APP) binds DR6 and triggers degeneration. Genetic support is provided by a common neuromuscular junction phenotype in mutant mice. Our results indicate that APP and DR6 are components of a neuronal self-destruction pathway, and suggest that an extracellular fragment of APP, acting via DR6 and caspase 6, contributes to Alzheimer's disease.
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Naturally occurring axonal pruning and neuronal cell death help to sculpt neuronal connections during development, but their mechanistic basis remains poorly understood. Here we report that b-amyloid precursor protein (APP) and death receptor 6 (DR6, also known as TNFRSF21) activate a widespread caspase-dependent self-destruction program. DR6 is broadly expressed by developing neurons, and is required for normal cell body death and axonal pruning both in vivo and after trophic-factor deprivation in vitro. Unlike neuronal cell body apoptosis, which requires caspase 3, we show that axonal degeneration requires caspase 6, which is activated in a punctate pattern that parallels the pattern of axonal fragmentation. DR6 is activated locally by an inactive surface ligand(s) that is released in an active form after trophic-factor deprivation, and we identify APP as a DR6 ligand. Trophic-factor deprivation triggers the shedding of surface APP in a b-secretase (BACE)-dependent manner. Loss-and gain-of-function studies support a model in which a cleaved amino-terminal fragment of APP (N-APP) binds DR6 and triggers degeneration. Genetic support is provided by a common neuromuscular junction phenotype in mutant mice. Our results indicate that APP and DR6 are components of a neuronal self-destruction pathway, and suggest that an extracellular fragment of APP, acting via DR6 and caspase 6, contributes to Alzheimer's disease.
The initial formative phase of nervous system development, involving the generation of neurons and extension of axons, is followed by a regressive phase in which inappropriate axonal branches are pruned to refine connections, and many neurons are culled to match the numbers of neurons and target cells [1] [2] [3] . The loss of neurons and branches also occurs in the adult after injury, and underlies the pathophysiology of many neurodegenerative diseases 1, 4 . Our understanding of regressive events in development remains fragmentary. Degeneration can result 'passively' from the loss of support from trophic factors such as nerve growth factor (NGF) [1] [2] [3] .
There is also evidence for 'active' mechanisms in which extrinsic signals trigger degeneration by means of pro-apoptotic receptors, including some members of the tumour necrosis factor (TNF) receptor superfamily such as p75NTR (also known as NGFR), Fas and TNFRSF1A (previously known as TNFR1) (Fig. 1a ) 5 . However, the full complement of degeneration triggers remains incompletely understood.
Our understanding of the intracellular mechanisms of neuronal dismantling is also incomplete. It is well documented that developmental neuronal cell body degeneration requires the apoptotic effectors BAX and caspase 3 (refs 6-8) ; pruning of a particular dendrite in Drosophila is also caspase-dependent 9, 10 . Developmental axonal degeneration similarly has many hallmarks of apoptosisincluding blebbing, fragmentation, and phagocytic clearing of debris by neighbouring cells 2, 4 . However, it has been argued that axonal degeneration is caspase-independent, because caspase 3 inhibitors block cell body but not axonal degeneration 8 (reflecting higher activation of caspase 3 in cell bodies compared to axons 11 ) , and because genetic manipulations to inhibit apoptosis did not block axonal degeneration in some models 12, 13 . These results indicated the existence of a caspase-independent program of axonal degeneration 1,2,4 , but its molecular nature has remained elusive. While studying the expression of all TNF receptor superfamily members 14 , we found that DR6-one of eight members possessing a cytoplasmic death domain (Fig. 1a) -is widely expressed by neurons as they differentiate and enter a pro-apoptotic state. DR6 is an orphan receptor 15 . In transfected cells, it triggers cell death in a Jun N-terminal kinase-dependent manner 16 . In vivo, it regulates lymphocyte development 17, 18 , but its involvement in neural development is unknown. Here we show that DR6 links passive and active degeneration mechanisms. After trophic deprivation, DR6 triggers neuronal cell body and axon degeneration. Because DR6 signals via BAX and caspase 3 in cell bodies, we revisited the involvement of caspases in axonal degeneration, and found that axonal degeneration indeed requires both BAX and a distinct effector, caspase 6. Our results also indicated that DR6 is activated by a prodegenerative ligand(s) that is surface-tethered but released in an active form after trophic deprivation. In searching for candidate ligands with these properties, we considered APP, a transmembrane protein that undergoes regulated shedding and is causally implicated in Alzheimer's disease [19] [20] [21] [22] , because we had previously found it to be highly expressed by developing neurons and especially axons (see later). Because Alzheimer's disease is marked by neuronal and axonal degeneration, we had long wondered whether APP participates in developmental degeneration. We show that an extracellular fragment of APP is indeed a ligand for DR6-as is a fragment of its close relative APLP2-that triggers degeneration of cell bodies via caspase 3 and axons via caspase 6, and we propose that this developmental mechanism is hijacked in Alzheimer's disease.
DR6 regulates neuronal death
To explore the involvement of the TNF receptor superfamily in neural development, we screened its 28 members by in situ hybridization in midgestation mouse embryos. We came to focus on DR6 (Fig. 1a) , because its messenger RNA is expressed at low levels in proliferating progenitors in the spinal cord, but is highly expressed by differentiating neurons within the spinal cord and adjacent dorsal root ganglia (DRG) (Fig. 1b) .
Because DR6-expressing neurons are becoming dependent for survival on trophic support at these stages, we examined whether DR6 regulates neuronal death after trophic-factor deprivation in vitro, focusing on three sets of spinal neurons: commissural, motor and sensory ( Supplementary Fig. 1a ). Initially, we found that short interfering RNA (siRNA) knockdown of DR6 protected commissural neurons from degeneration ( Supplementary Fig. 2 ). This prompted us to screen monoclonal antibodies to DR6 for their ability to mimic this protection; we selected antibody 3F4 (anti-DR6.1). When embryonic day (E)13.5 rat dorsal spinal cord explants are cultured for 24 h, commissural cell bodies and axons are healthy, but they degenerate if cultured for 24 h longer 23 ; anti-DR6.1 inhibited this degeneration (Fig. 1c, f) , mimicking DR6 knockdown. Anti-DR6.1 also protected sensory neurons from E12.5 mouse DRGs cultured for 48 h with NGF, and motor neurons from E12.5 mouse ventral spinal cord explants cultured for 24 h with brain-derived neurotrophic factor (BDNF) and neurotrophin 3 (NTF3, also known as NT3): when these cultures were deprived of trophic factor and cultured for 24 h longer, they showed massive cell death and axonal degeneration, which were largely inhibited by anti-DR6.1 (Fig. 1d-f and Supplementary Fig. 1b ). Similar protection was observed when DRGs or ventral explants from a DR6 null mutant 17 were deprived in the absence of anti-DR6.1 ( Supplementary Fig. 4b and data not shown), confirming that anti-DR6.1 is function-blocking. DR6 inhibition (by antibody, siRNA or genetic deletion) caused a delay rather than a complete block, because more degeneration was observed in each case 24-48 h later (Fig. 2b, Supplementary Fig. 4b and data not shown). Consistent with a delay, there was a higher motor-neuron number at E14.5 in the DR6 mutant, but this returned to the wild-type level by E18 ( Supplementary Fig. 3 ), after the cell death period. Thus, antagonizing DR6 delays the death of several neuronal populations in vitro and in vivo.
DR6 regulates axonal pruning DR6 protein is expressed not just by cell bodies (data not shown) but also by axons ( Supplementary Fig. 4a) inhibition might therefore reflect a direct role for DR6 in axons. To explore this, we used compartmented ('Campenot') chambers 24 ( Fig. 2a) . Sensory neurons are placed in a central chamber containing NGF; their axons grow under a partition into NGF-containing sidechambers. Fluid exchange between the chambers is limited, so NGF deprivation in a side-chamber elicits local axon degeneration while sparing cell bodies 24 . Locally deprived axons degenerate in a stereotypical manner with initial signs by 6 h and extensive degeneration by 12-24 h, but when anti-DR6.1 was added to the deprived sidechamber, degeneration was blocked at 24 h and still largely impaired at 48 h (Fig. 2b) . A similar delay was observed when axons of neurons from DR6 knockout mice were locally deprived, but in the absence of anti-DR6.1 ( Supplementary Fig. 4b, c) . Thus, DR6 function is required in axons for degeneration.
To determine whether DR6 functions in axonal pruning in vivo, we studied the well-characterized retino-collicular projection, which develops from an initially exuberant projection of retinal ganglion cell (RGC) axons to a focused termination zone in the superior colliculus. All temporal RGC axons initially extend into posterior superior colliculus, well past their future termination zone in anterior superior colliculus (Supplementary Fig. 5a ). This diffuse projection is then refined by selective degeneration of inappropriate axon segments 2 , such that by postnatal day (P)6 in wild-type mice few axon segments persist in areas well beyond the termination zone, as revealed by focal injection of the lipophilic dye DiI into temporal retina (Fig. 2c, d and Supplementary Fig. 5a , b). In contrast, in P6 DR6 mutant mice, many more RGC axons and arbors are present in areas far from the termination zone ( we found an 83% increase in axon-positive domains more than 400 mm from the termination zone ( Supplementary Fig. 5f ) in DR6 2/2 (n 5 7) compared to wild-type mice (n 5 7; P , 0.05, Student's t-test). The defect at P6 represents a delay in pruning, not a complete block, as assessed by examining labelled axons at P4, P5, P6 and P9: at each age, the mutant has more extraneous axons than the wild-type, and fewer are observed in both wild-type and mutant at each age compared to earlier time points, but by P9 the mutant and wild-type projections are indistinguishable (data not shown). Thus, blocking DR6 function delays pruning of sensory axons in vitro and retinocollicular axons in vivo.
Caspase 6 regulates axonal degeneration
Because DR6 regulates both cell body apoptosis and axonal degeneration, we revisited whether an apoptotic pathway is also involved in axons. In support, we found that BAX, an effector in the intrinsic apoptotic pathway, is required in axons, because local sensory axon degeneration in Campenot chambers was blocked by the genetic deletion of Bax (Fig. 3a) or by local addition of a BAX inhibitor (for example, Supplementary Fig. 10b ). Consistent with evidence that caspase 3 mediates cell body but not axon degeneration 8, 11 , we found that procaspase 3 is highly enriched in cell bodies, and that zDEVD-fmk, an inhibitor of effector caspases 3 and 7, blocked cell body but not axon degeneration (Fig. 3b, c and Supplementary Fig.  6a -c). There is, however, a third effector caspase, caspase 6. We found that procaspase 6 is expressed in both cell bodies and axons, and that the caspase 6 inhibitor zVEID-fmk blocked degeneration of sensory, motor and commissural axons (Fig. 3b, c and Supplementary Fig.  6a -c), suggesting that caspase 6 regulates axonal degeneration. We verified these results using RNA interference in sensory and commissural neurons: Casp3 knockdown protected cell bodies significantly but had only a minor protective effect on axons, whereas Casp6 knockdown protected axons significantly with only minor effect on cell bodies (Fig. 3d, e) . Thus, distinct caspases mediate cell body and axon degeneration.
To visualize caspase activation, we first used the fluorescent reporters FAM-DEVD-fmk (for caspase 3 and 7) and FAM-VEID-fmk (for caspase 6), which bind covalently to activated target caspases. In NGF-deprived sensory neurons, the caspase 3/7 reporter labelled cell bodies but not axons, consistent with a previous study 11 ; in contrast, caspase 6 reporter labelling was observed in both cell bodies and axons, and axonal labelling occurred in regularly spaced 'puncta', giving a beads-on-a-string appearance ( Supplementary Fig. 6f ). To control for reporter specificity, we used a selective antibody to cleaved caspase 6 and observed a similar punctate pattern in axons (Fig. 3f, g ), whereas antibodies to cleaved caspase 3 only label cell bodies 11 . Caspase 6 activation was confirmed biochemically ( Supplementary Fig. 6e ). Interestingly, caspase 6 activation appeared at sites of microtubule fragmentation (assessed by the loss of tubulin immunoreactivity) (Fig. 3f, g ), suggesting that caspase 6 activation drives microtubule destabilization. Punctate caspase 6 activation was markedly reduced by anti-DR6.1 ( Fig. 3f ) and abolished in Bax 2/2 neurons (not shown), suggesting that caspase 6 acts downstream of BAX in the pathway triggered by DR6. However, the possibility of feedback loops in apoptotic pathways makes this interpretation tentative.
Regulated shedding of a DR6 ligand(s)
As DR6 is a receptor-like protein, we addressed whether it is activated by a ligand(s). If so, the DR6 ectodomain might be capable of binding the ligand(s) and blocking its action (Fig. 4a) . Consistent with this, the DR6 ectodomain fused to human Fc (DR6-Fc) mimicked anti-DR6.1 in delaying degeneration (Fig. 4a-c and Supplementary Figs 7a and 13). To search for DR6 binding sites on axons and in conditioned medium, we used the DR6 ectodomain fused to alkaline phosphatase (DR6-AP). Purple alkaline phosphatase reaction product was observed on sensory and motor axons cultured with trophic factors when they were pre-incubated with DR6-AP but not with alkaline phosphatase alone, but binding was markedly reduced after trophic deprivation ( Supplementary Fig. 7b, c) . To control for the loss of axonal membrane, we blocked degeneration using a BAX inhibitor (data not shown) or using neurons from Bax 2/2 mice (Fig. 4d ) and observed an even greater reduction in DR6-AP binding (residual binding seen without BAX inhibition might reflect nonspecific binding to degenerating axons). To determine whether DR6-binding sites were shed, we collected medium conditioned by sensory axons (in Campenot chambers) or motor neurons (in explant culture) (a BAX inhibitor was added to prevent nonspecific release resulting from degeneration). Proteins were separated on non-reducing gels, blotted to nitrocellulose, and probed with DR6-AP. Little signal was seen in medium conditioned by either neuronal type in the presence of trophic factor. However, 48 h after trophic deprivation, DR6-AP bound a prominent band around ,35 kDa and a minor band around ,100 kDa in both cultures (Fig. 4e) . Together, these results support a 'ligand activation' model in which a prodegenerative DR6 ligand(s) is present on the neuronal surface and inactive, but is shed into medium in an active form after trophic deprivation (Fig. 4f) , allowing it to bind and activate DR6.
N-APP is a regulated DR6 ligand
Several properties of APP made it a candidate for a DR6 ligand: (1) it is highly expressed by developing spinal and sensory neurons and their axons (Fig. 4g) , (2) its ectodomain can be shed in a regulated fashion 19, 20 , and (3) it is tied to degeneration through its links to Alzheimer's disease [19] [20] [21] [22] . In an initial experiment, we found that DR6-AP bound APP expressed in COS-1 cells (Supplementary Fig.  8a ). This prompted us to test whether the bands detected by DR6-AP in conditioned medium (Fig. 4e) represent APP ectodomain fragments. APP is cleaved by a-or b-secretases (including, in neurons, BACE1; ref. 25) at distinct sites in its juxtamembrane region (Fig. 4h) to release ,100-kDa ectodomain fragments termed sAPPa or sAPPb, respectively 19, 20 . We probed conditioned medium with a polyclonal antibody to the APP N terminus (anti-N-APP(poly), which also binds the APP relative APLP2; see later) and an antibody selective for the carboxy-terminal epitope of sAPPb exposed by BACE cleavage (anti-sAPPb) (Fig. 4h) . Notably, anti-N-APP(poly) detected similar bands to those detected by DR6-AP: a major band at ,35 kDa and a minor band at ,100 kDa, both highly enriched after trophic deprivation (Fig. 4i) ; anti-sAPPb detected a minor ,100-kDa band and a major ,55-kDa band (Fig. 4i) , also both enriched after trophic deprivation. These results indicate that trophic deprivation triggers BACE cleavage of APP to yield the ,100-kDa sAPPb (detected by both antibodies), which undergoes a further cleavage(s) to yield a ,55-kDa C-terminal fragment (detected by anti-sAPPb) and a ,35-kDa N-terminal fragment (detected by anti-N-APP(poly)) that we term N-APP. The site of additional cleavage(s) is unknown, but on the basis of fragment sizes it is expected to be around the junction between the APP 'acidic' and 'E2' domains (amino acid 286); indeed, recombinant APP(1-286) ran at ,35 kDa and was detected with anti-N-APP(poly) (Fig. 4j) , similar to N-APP.
Supporting cleavage of APP by BACE, we found that APP expression on the surface of cultured sensory and motor axons, as assessed with anti-N-APP(poly) and with antibody 4G8 to the APP juxtamembrane region (Fig. 4h) , is high in the presence of trophic factor but lost after trophic deprivation; the surface loss was blocked by three structurally divergent BACE inhibitors-OM99-2, BACE inhibitor IV, and the highly selective AZ29 (ref. 26 ) but not the a-secretase inhibitor TAPI (Fig. 4k, Supplementary Figs 9a-c and  10a , and data not shown). Interestingly, 4G8 partially inhibited surface loss ( Supplementary Fig. 9d ), presumably through the steric hindrance of BACE. Loss of surface APP occurred progressively and in 'patches', with little lost at 3 h, more at 6-12 h, and most lost by 24 h (Fig. 4k, Supplementary Fig. 10b and data not shown). Total APP visualized after permeabilization did not change detectably ( Supplementary Fig. 10b ). Surface loss was not affected by BAX or caspase 6 inhibitors, or in neurons from Bax 2/2 mice ( Fig. 4k and Supplementary Figs 9c and 10c) .
The marked similarly of bands detected by anti-N-APP(poly) and DR6-AP suggested that DR6 binds N-APP. Indeed, depletion of conditioned medium with anti-N-APP(poly) eliminated DR6-AP binding sites (Fig. 4i) , and purified DR6-Fc bound to purified recombinant APP(1-286) in pull-down (Fig. 4j) and enzyme-linked Fig. 6d ). f, Detection of caspase 6 activation in sensory axons with a cleaved caspase-6-specific antibody (left; TuJ1 double-label on right). Punctate activation of caspase 6 after NGF deprivation (16 h, middle panel) was reduced by anti-DR6.1 (bottom panel). g, Confocal section of a field from f shows that active caspase 6 puncta correspond to sites of tubulin loss (fraction non-overlapping: 82 6 3.5%; mean 6 s.e.m., n 5 8 fields). Scale bars, 75 mm (a, d), 100 mm (b), 50 mm (c, f) and 25 mm (g).
immunosorbent assay (ELISA) (Supplementary Fig. 8c ) assays. The interaction detected by ELISA is of high affinity (effector concentration for half-maximum response (EC 50 ) 5 ,4.6 nM). The interaction of DR6-AP with full-length APP expressed in COS cells was also of high affinity (half maximal saturation 5 ,1.3 nM) ( Supplementary Fig. 8a, b) . This binding was blocked by anti-N-APP(poly) (data not shown) and anti-DR6.1 ( Supplementary Fig.  8a ), consistent with APP being a functional DR6 ligand.
Antibodies 4G8 and anti-sAPPb used earlier are highly specific for APP. However, like other antibodies to the N terminus of APP 27 , anti-APP(poly) also binds the close APP relative APLP2 (data not shown). We found that a recombinant N-terminal fragment of APLP2 also binds DR6 (Supplementary Fig. 11a ). Thus, APLP2 might contribute with APP to the bands detected on western by DR6-AP. Indeed, an antibody selective for the APLP2 N terminus detected a shed fragment in conditioned medium after trophic deprivation ( Supplementary Fig. 11b ). The relative contribution of APP and APLP2 fragments to DR6-AP binding sites remains to be determined.
To evaluate receptor specificity, we examined by pull-down the binding of APP (1-286) to ectodomains of the seven other death-domain-containing members of the TNF receptor superfamily, and two orphan members. Only binding to p75NTR was observed ( Supplementary Fig. 8d ), suggesting that p75NTR might serve as an alternative route for APP effects in some settings; however, the affinity was considerably lower (EC 50 5 ,300 nM by ELISA; Supplementary Fig. 8e ). Consistent with DR6 being the chief APP receptor in our systems, a fusion of APP(1-286) and alkaline phosphatase bound to sensory axons in culture, but the binding was significantly reduced by anti-DR6.1 or by using DR6 knockout neurons ( Supplementary Fig. 12a, b) ; residual binding may represent background or binding to another receptor(s), possibly p75NTR.
Necessity and sufficiency of N-APP
To test whether the N terminus of APP contributes to degeneration, we performed loss-of-function studies. Degeneration of sensory and commissural axons in response to trophic deprivation was inhibited by anti-N-APP(poly) (Fig. 5a, d) , which also inhibited the death of sensory neuron cell bodies ( Supplementary Fig. 13a, b) , without affecting the loss of surface APP after trophic deprivation (Supplementary Fig. 13c ). Antibody 22C11 (ref. 28) to the APP N terminus (Fig. 4h ) also inhibited sensory axon degeneration (data not shown). Because both antibodies also bind APLP2 (ref. 27 ), we performed a more selective blockade using RNA interference. Knockdown of App in sensory neurons significantly impaired both axon degeneration and cell body death after trophic withdrawal (Fig. 5b) . These results support the involvement of an N-terminal fragment of APP in degeneration. In further support, BACE inhibitors impaired degeneration of sensory axons and cell bodies (Fig. 5c and Supplementary Figs 13a, b and 14) and of commissural axons (Fig. 5d) after trophic deprivation. The selective BACE inhibitor AZ29 blocked degeneration at concentrations consistent with its cellular half-maximal inhibitory concentration (IC 50 ) of 470 nM 26 ( Supplementary Fig. 14a ).
Importantly, axonal degeneration block by BACE inhibitors could be reversed by adding purified APP(1-286) to sensory (Fig. 5c) and commissural ( Fig. 5d) neurons, showing that the N terminus of APP is sufficient to trigger degeneration. This effect was largely blocked by anti-DR6.1 ( Supplementary Fig. 14b ), consistent with DR6 being the most important functional receptor in these cells. Block of sensory cell body degeneration by BACE inhibitors could similarly be reversed by the addition of APP(1-286), albeit at higher concentrations ( Supplementary Fig. 13a, b) . Together, these results support the model that shed N-APP activates DR6 to trigger degeneration. Degeneration of sensory axons caused by APP in the presence of BACE inhibitor was blocked if NGF was present (50 ng ml 21 ; Fig. 5c ), indicating that trophic factors also inhibit signalling downstream of DR6.
Role of amyloid-b in physiological degeneration BACE cleavage of APP is followed by c-secretase cleavage, yielding amyloid-b peptides [19] [20] [21] [22] (Figs 4h and 6c) . Because amyloid-b peptides can be neurotoxic 21, 22 , we examined whether they contribute to degeneration. The synthetic amyloid-b peptide Ab(1-42) triggered degeneration in our assays, and an antibody directed at amino acids 33-42 of amyloid-b (anti-Ab(33-42); Fig. 4h ) blocked this effect ( Supplementary Fig. 9a, e) , but did not block degeneration after trophic deprivation (Fig. 5e) . Conversely, degeneration induced by synthetic Ab(1-42) was not blocked by the genetic deletion of DR6 (data not shown), indicating that amyloid-b operates by a mode of action distinct from the physiological degeneration mechanism studied here. Antibody 4G8 used earlier, which binds amyloid-b residues 17-24 ( Fig. 4h) , also blocked the degenerative effect of Ab(1-42) ( Supplementary Fig. 9e ), but unlike anti-Ab(33-42) it partially inhibited degeneration after trophic deprivation (Fig. 5e) . However, as mentioned, 4G8 also partially inhibits the loss of surface . Quantification is shown to the right for all panels (a-e). b, In dissociated sensory neurons, siRNA knockdown of App ( Supplementary Fig. 13d ) significantly reduces axon degeneration 24 h after trophic deprivation, and partially reduces cell body death. c, Local degeneration of sensory axons in Campenot chambers (NGF deprivation, 24 h) was inhibited by the local addition of BACE inhibitor (BACEi) OM99-2 (10 mM). Purified APP(1-286) added locally restored axonal degeneration, an effect inhibited by 50 ng ml 21 NGF (right). d, Degeneration of commissural neurons and axons at 48 h was inhibited by anti-N-APP(poly) (20 mg ml 21 ) or BACE inhibitor OM99-2 (10 mM), but restored by APP (1-286) . e, Effect of amyloid-b antibodies on sensory axon degeneration (NGF deprivation, 24 h). 4G8 partially inhibited, whereas anti-Ab(33-42) did not. Scale bars 50 mm (a, c, e), 40 mm (b) and 200 mm (d). All data are mean and s.e.m. for n 5 3 replicates.
APP. In contrast, the APP epitope bound by anti-Ab(33-42) is buried in the cell membrane, so anti-Ab(33-42) does not bind intact APP nor inhibit its surface loss ( Supplementary Fig. 9a, b, d ). Because anti-Ab(33-42) does not protect, we attribute the partial protective effect of 4G8 to its ability to inhibit APP shedding, not its ability to block amyloid-b toxicity. Because 4G8 does not bind APLP2, its ability to protect also supports the sufficiency of APP in mediating degeneration.
Evidence for an APP-DR6 interaction in vivo To seek evidence for an APP-DR6 interaction in vivo, we examined whether the DR6 knockout exhibits any similar phenotype to those reported in the App knockout-or, given the potential for redundancy, in compound mutants of App with Aplp2. One phenotype observed at the neuromuscular junction in the App 2/2 Aplp2
double knockout is suggestive of a potential pruning defect. In wild-type animals, motor axons normally terminate at synaptic sites (Fig. 6a) . In App 2/2 Aplp2 2/2 double knockouts, however, there is a highly penetrant presence of nerve terminals past endplates 29 . Notably, a similar phenotype was observed in the DR6 mutant: rather than terminating at endplates, many terminals were present beyond, giving characteristic finger-like protrusions (Fig. 6a, b) . It is not known whether this phenotype reflects a failure to retract or excessive sprouting. Nevertheless, the similarity of phenotypes supports the view that APP signals via DR6 in regulating axonal behaviour in vivo. In this system, APP and APLP2 appear redundant because the axonal phenotype is seen only in App 2/2 Aplp2 2/2 double mutants, not single mutants 29 . Whether they are non-redundant in other systems remains to be determined.
Discussion
Our results reveal a mechanism, the 'APP-death-receptor' mechanism (Fig. 6c) , in which trophic deprivation leads to the cleavage of surface APP by b-secretase, followed by further cleavage of the released fragment by an as yet unidentified mechanism (probably near the junction of APP acidic and E2 domains). This then yields an N-terminal ,35-kDa fragment (N-APP) which binds DR6, triggering caspase activation and degeneration of both neuronal cell bodies (via caspase 3) and axons (via caspase 6). Whether the second cleavage is required for degeneration remains to be determined. Degeneration induced by added APP(1-286) was blocked when sufficient trophic factor was present, indicating that trophic factor not only prevents initiation of the APP cleavage cascade, but also blocks signalling downstream of DR6, providing a fail-safe mechanism to protect if DR6 is inappropriately activated in an otherwise healthy neuron.
DR6: an accelerator of self-destruction
In all settings examined, antagonizing DR6 resulted in a delay, rather than a complete block, in neuronal death and axonal pruning. DR6 is therefore best thought of as an accelerator of degeneration-neurons and axons activate it for swift self-destruction when they become atrophic, but without it they have other, slower, ways of achieving that end, perhaps involving other pro-apoptotic receptors 5 or intrinsic mechanisms. This function contrasts that of the DR6 relative p75NTR (which can mediate degeneration when overexpressed 11 or when activated by a neurotrophin in neurons lacking the cognate TRK (also known as NTRK) receptor 5 ). p75NTR is more restricted to specific neuronal classes than DR6, and its genetic deletion provided only modest protection of sensory axons in the first 36 h after trophic deprivation ( Supplementary Fig. 15 ), as reported previously for sympathetic axons 30 . In sympathetic neurons, p75NTR is thought to mediate competition for NGF: cells with high NGF/TRKA signalling upregulate expression of BDNF, which acts via p75NTR to trigger degeneration of neighbouring neurons with less robust NGF/TRKA signalling 30, 31 . This mechanism shares with ours the expression of a prodegenerative ligand(s) by the neurons themselves. However, the DR6 ligand APP is activated by trophic-factor deprivation, whereas p75NTR ligand expression is increased by trophic-factor stimulation 31 . Thus, p75NTR ligands are released by 'strong' neurons to kill 'weak' neurons (a paracrine prodegenerative effect) 31 , whereas APP gets activated within weak neurons to accelerate self-destruction ) P0 diaphragm muscle, few axons (green, neurofilament (NF) and synaptophysin (SYP) stain) overshoot endplates (red, fluorescent a-bungarotoxin (BTX) stain), and those that do are short, but in DR6 mutants more overshoot and many are long (arrowheads). Scale bar, 60 mm (left four panels) and 15 mm (right four panels). b, The number of axons overshooting by .50 mm (mean and s.e.m., n 5 3 wild-type, 4 mutants); this underestimates the effect, because overshooting axons are longer in mutants. NMJ, neuromuscular junction. c, The APP-deathreceptor mechanism is shown. Trophic factor (TF)-deprivation triggers the cleavage of surface APP by b-secretase, releasing sAPPb, which is further cleaved by an unknown mechanism ('?') to release N-APP. This then binds DR6 to trigger degeneration through caspase 6 in axons and caspase 3 in cell bodies. Also illustrated is cleavage by c-secretase to release amyloid-b (Ab) and the APP intracellular domain (AICD).
triggered by trophic deprivation or perhaps other insults (an autocrine prodegenerative effect).
Caspase 6 mediates axonal degeneration
The intracellular mechanisms of axonal degeneration and their relation to apoptosis have been unclear. Our results indicate that developmental axonal degeneration does involve an apoptotic pathway, but with a non-classical effector, caspase 6. Epistatis analysis supports a linear activation model from DR6 to BAX to caspase 6, but does not exclude the possibility that active caspase 6 might feedback, for example, to accelerate the process; in this context, it is intriguing that the APP cytoplasmic domain is a caspase 6 substrate 32 . Activation of caspase 6 by trophic deprivation occurs in a punctate pattern in axons, leading to a beads-on-a-string appearance, and sites of punctate caspase 6 activation correspond to sites of microtubule fragmentation. Caspase 6 might trigger microtubule destabilization by cleaving microtubule associated proteins such as TAU (also known as MAPT), a documented target of caspase 6 (refs 33, 34) ; in a recent proteomic analysis, almost half the identified caspase 6 targets were cytoskeleton-associated 35 .
Ligands, receptors for self-destruction Although p75NTR also binds APP(1-286), DR6 binds with a much higher affinity, and blocking DR6 function largely blocks both APP(1-286) binding to sensory axons and degeneration triggered by APP(1-286). Thus, DR6 seems to be the major functional APP receptor in these neurons, although p75NTR might contribute in other contexts. Conversely, APP may not be the only DR6 ligand: APLP2, which is coexpressed with APP in many neurons 27 , may also contribute to degeneration, because an N-terminal fragment is shed in response to trophic deprivation, can bind DR6, and can trigger degeneration when added exogenously (Supplementary Fig. 16 ). Future studies will define the relative contributions of APP and APLP2 in different neuronal populations.
The finding of similar neuromuscular junction phenotypes in DR6 and App 2/2 Aplp2 2/2 mutants supports a ligand-receptor interaction, and indicates that APP and APLP2 both contribute in this system. The aberrant axonal extensions seen could reflect an impairment of pruning, or, alternatively, a failure of axons to stop; of note, the APP ectodomain has been implicated in neurite growth inhibition 36 . Previous studies have not reported changes in neuronal cell death in vivo in App mutants, either singly or in combination with Aplp1 and/or Aplp2 mutations 37, 38 . However, such studies did not examine spinal cord or sensory ganglia, nor involve time-course analysis to evaluate possible delays in degeneration. In vitro analysis of cortical neurons from mutants has given divergent results about their basal survival rates and susceptibility to glutamate excitotoxicity [37] [38] [39] , but their response to trophic deprivation has not been reported.
In recent findings paralleling ours, trophic deprivation was found to trigger BACE cleavage of APP in PC12 cell-derived neurons and primary hippocampal neurons, and degeneration was reduced by App knockdown (in PC12 cells) and BACE inhibition 40, 41 . The prodegenerative function of APP was, however, attributed to amyloid-b, because antibodies to amyloid-b inhibited degeneration 40, 41 . We too observed protection by antibody 4G8, but attribute this to the ability of 4G8 to bind full-length APP and inhibit cleavage, because a different anti-amyloid-b antibody that does not bind native APP inhibited neither shedding nor physiological degeneration, but blocked the toxic action of added amyloid-b. Conversely, the toxic effect of amyloid-b was not blocked by DR6 inhibition. It was also found that a c-secretase inhibitor, which reduced amyloid-b production after BACE cleavage, inhibited degeneration 40, 41 . We too found that c-secretase inhibitors can partially inhibit degeneration of commissural and sensory axons (Supplementary Fig. 17 ), but c-secretase has many substrates, and it is possible that the efficient activation of DR6 signalling requires a distinct c-secretase-dependent process. Thus, our results argue against the involvement of amyloid-b in initiating DR6-dependent degeneration in the neurons studied here, but this does not exclude its possible involvement in other neurons, or at later times in these neurons to augment the effects of APP-DR6 signalling.
APP-DR6 signalling and neurodegeneration APP is expressed in adult brain and upregulated in damaged axons 42 . DR6 is also highly expressed in adult brain (Supplementary Fig. 18 ). Given our findings, it is reasonable to assume that the APP-deathreceptor mechanism might contribute to adult plasticity, or to neurodegeneration after injury or in disease. Interestingly, DR6 is upregulated in injured neurons 43 , raising the question as to whether overexpressed DR6 in neurons can trigger ligand-independent degeneration, as reported for p75NTR 11 . Given the genetic evidence linking APP and its cleavage to Alzheimer's disease, we propose that signalling of APP via DR6 (and possibly p75NTR) may in particular contribute to the initiation or progression of Alzheimer's disease, either alone or in combination with other proposed APP-dependent mechanisms, such as amyloidb toxicity 21, 22 or effects of the APP intracellular domain 44 . Of note, previous studies showed immunoreactivity for the APP N terminus associated with Alzheimer's plaques 45, 46 , DR6 maps to chromosome 6p12.2-21.1, near a putative Alzheimer's disease susceptibility locus 47 , and sites of DR6 mRNA expression in adult brain correlate in an intriguing way with known sites of dysfunction in Alzheimer's: very high in hippocampus, high in cortex, but low in striatum ( Supplementary Fig. 18 ), and high in forebrain cholinergic neurons 48 , for instance. In addition, activated caspase 6, a downstream DR6 effector, is associated with plaques and tangles in Alzheimer's disease, and with mild cognitive impairment 34, 49 , consistent with the possible activation of caspase 6 in neuritic processes by the APPdeath-receptor mechanism (caspase 6 is also implicated in Huntington's disease 50 ). Although these results are compatible with the involvement of APP-DR6 signalling in Alzheimer's, it is less clear how the mechanism fits with genetic evidence implicating altered c-secretase processing in this disease [19] [20] [21] [22] . However, the fact that c-secretase inhibitors antagonize DR6-dependent degeneration hints at a possible relationship.
Thus, further study is required to determine the full implications of the APP-death-receptor mechanism in development, adult physiology and disease. Nonetheless, our results already tie APP to a new mechanism for neuronal self-destruction in development, and suggest that the APP ectodomain, acting via DR6 and caspase 6, contributes to the pathophysiology of Alzheimer's disease.
METHODS SUMMARY
Antibodies to the following targets were used: procaspase 3 (1:200, Upstate), active capsase 3 (1:200, R&D), procaspase 6 (1:200, Stratagene), active caspase 6 (1:100, BioVision), Tuj1 (1:500, Covance), p75NTR (Chemicon), 2H3 (1:200, DSHB), Islet1/2 (1:100, Santa Cruz Biotech), N-APP (polyclonal, 1:100, Thermo Fisher Scientific; monoclonal 22C11, Calbiochem), DR6 (R&D), NGF (Abcam and Genentech), BDNF (Calbiochem), NT3 (Genentech), amyloid-b (4G8, Covance), the C-terminal cleavage-specific anti-amyloid-b antibody (antiAb(33-42), Sigma), and the C-terminal cleavage site of sAPPb (Covance). Monoclonal antibodies to human DR6 ectodomain fused with human Fc (A.N., K. Dodge, V. Dixit and M.T.L., manuscript in preparation) were screened for binding to murine DR6 and block of commissural neuron degeneration. Proteins used were: netrin-1 (R&D), NGF (Roche), BDNF and NT3 (Calbiochem), and control IgG (R&D). Transiently expressed murine DR6 ectodomain (amino acids 1-349) fused to human Fc, His-tagged human APP , and APP(1-286) and APLP2(1-300) fused to human Fc, were affinitypurified from CHO cell supernatants (similar results were obtained using APP(1-286) and APP(1-306), Novus Biologicals). Inhibitors were used against: caspase 3 (Z-DEVD-FMK, Calbiochem), caspase 6 (Z-VEID-FMK, BD Pharmingen), BACE (OM99-2, Calbiochem; BACE inhibitor IV, Calbiochem; AZ29, Genentech), c-secretase (DAPT, Calbiochem).
See Methods for details of in situ hybridization and immunohistochemistry, explant, dissociated, and Campenot chamber cultures, siRNA transfection,
